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Neuronal expression of major histocompatibility complex I (MHC-I) has been implicated in
developmental synaptic plasticity and axonal regeneration in the central nervous system
(CNS), but recent findings demonstrate that constitutive neuronal MHC-I can also be
involved in neurodegenerative diseases by playing a neuroinflammtory role. Recent reports
demonstrate its expression in vitro and in human postmortem samples and support
a role in neurodegeneration involving proinflammatory cytokines, activated microglia
and increased cytosolic oxidative stress. Major histocompatibility complex I may be
important for both normal development and pathogenesis of some CNS diseases including
Parkinson’s.
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INTRODUCTION
The major histocompatibility complex (MHC) gene family
encodes molecules on the surface of cells that enable the immune
system to recognize presented self- and foreign-derived peptides
(Chemali et al., 2011). The MHC genes (in human, HLA-A,
-B, -C and HLA-DP, -DM, -DOA, -DOB, -DQ, -DR; in mouse,
H-2-K, -D, -L, and 2-I-A and I-E allomorphs) are generally
divided into three categories: class I, II or III. Class I MHC
(MHC-I) molecules are expressed by nearly every mammalian
cell class, while MHC class II (MHC-II) molecules are restricted
to cells of the immune system, such as macrophages and lym-
phocytes. In human, genes encoding for MHC-I and MHC-II
have a large number of alleles, leading to a great diversity of
sets of MHC molecules in our species. MHC class III genes
code for other immune system proteins, including components
of the complement system and proinflammatory cytokines, as
well as proteins not involved in immune function (Janeway et al.,
2001).
MHC-I consists of two non-covalently linked polypep-
tide chains, known as alpha (α) and beta 2 microglob-
ulin (β2m) chains (Cresswell et al., 2005). The complex
can bind a large set of antigenic peptide fragments derived
from degradation of intracellular proteins by the proteasome,
which requires the “transporter associated with antigen pro-
cessing” (TAP; Van Kaer et al., 1992). The MHC-I/peptide
complex is then transferred to a vesicle that fuses with the
plasma membrane to present the peptide fragment extracel-
lularly. These antigens can then be identified by cytotoxic T
lymphocytes (CTLs) or natural killer cells as “self ” or “non-
self ” peptides, which leads to various responses depending on
their receptors (Fleischer et al., 1986; Pawelec et al., 1986). If
CTLs recognize the peptides as non-self antigens, they kill the
presenting cells through the Fas or perforin pathways and/or
indirectly by the release of cytokines (Andersen et al., 2006;
Figure 1).
It has generally been presumed that the central nervous system
(CNS) is immune-privileged and that MHC-I is not expressed
by neurons (Lampson, 1995). However, accumulating data have
demonstrated MHC-I expression by subsets of neurons in both
adult and developing mammalian brain (for review, see Cullheim
and Thams, 2010). Many of these reports describe a role for neu-
ronal MHC-I in synaptic plasticity, brain development and axonal
regeneration. Recent studies suggest that neuronal expression of
this molecule is involved in neuroinflammatory processes and
participates in immune-mediated neurodegeneration. In partic-
ular, there have been many reports linking neuroinflammation
and Parkinson’s disease (PD; Tansey and Goldberg, 2010), and
new data from our group suggests that expression of MHC-I
by substantia nigra (SN) and locus coeruleus (LC) neurons may
be involved in these inflammatory processes (Cebrián et al.,
2014).
This review summarizes the pattern of expression and the
different implications of neuronal MHC-I in the brain, and
focuses in particular in the potential role of constitutive MHC-I
expression by specific subsets of neurons in neurodegenerative
diseases such as PD.
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FIGURE 1 | Model of a CD8+ cytotoxic T cell targeting an MHC-I
expressing cell. Intracellular antigens are digested by the proteasome into
small peptides. A specialized carrier, the transporter associated with
antigen processing (TAP) complex, translocates the peptide into the
endoplasmic reticulum (ER), allowing the antigen to bind MHC class I,
which consists of an alpha and beta 2 microglobulin (β2m) chain.
Endoplasmic reticulum-derived vesicles that contain the complex fuse with
the Golgi. The complex is then packaged in secretory vesicles that fuse
with the plasma membrane to insert the complex on the cell surface.
Major histocompatibility complex I molecules present antigens to CD8+
cytotoxic T cells. The T cell CD8+ molecule recognizes MHC-I, while TCRs
recognize specific antigenic peptides. The TCR complex contains CD3 and
ζ(zeta) chains. Once the CD8+ T cell recognizes the target cell, apoptosis
can occur in two ways: one uses the Fas ligand protein, which is
expressed on the surface of the CD8+ T cells and binds to the Fas
receptor on the target cell, which triggers apoptosis through the classical
caspase cascade. The other uses secretion of granzyme B and perforin
from T cell granules into the intercellular space between the cells.
PATTERN OF MHC-I EXPRESSION IN CNS NEURONS
Although the presence of MHC-I in the mature rodent CNS
was for many years thought to be confined to glial cells (Wong
et al., 1984), ensuing reports demonstrate MHC-I expression by
some neuronal populations, both in vitro, usually triggered by
exposure to interferon gamma (IFN-γ), and in vivo. The initial
such study showed that MHC-I genes expression were induced
by IFN-γ in cultured rat hippocampal neurons (Neumann et al.,
1995).
Subsequently, mRNA for MHC-I was identified in nuclei of
neonatal and adult rodent brain including the SN, brainstem
motor neurons (Lindå et al., 1999), lateral geniculate nucleus
(LGN), cortex, hippocampus (Huh et al., 2000) and cerebel-
lum (Letellier et al., 2008). In aged rat motoneurons, mRNA
for MHC-I and β2m increased with age (Edström et al.,
2004).
Multiple groups reported expression of MHC-I subunits by
immunolabel in CNS regions including cingulate cortex and hip-
pocampus (Needleman et al., 2010; Liu et al., 2013), with expres-
sion gradually decreasing as neonatal mice reached adulthood
(Liu et al., 2013). A recent study shows that MHC-I proteins are
widely expressed in the developing mouse CNS at mid-gestation
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(E9.5–10.5), including the neuroepithelium and olfactory placode
(Chacon and Boulanger, 2013).
In human brain, MHC-I expression was initially reported in
microglia and endothelial cells of the hippocampus in control
individuals and Alzheimer’s disease patients (Tooyama et al.,
1990), but not in neurons. In contrast, MHC-II immunolabeling
microglia, but not neurons, was shown in the SN of patients
with Alzheimer’s disease and PD (McGeer et al., 1988), and in
the hippocampus of patients with dementia with Lewy bodies
(Imamura et al., 2005).
The neuronal expression of MHC-I in human brain has to date
only been reported in a few studies. The first was a study of a child-
hood viral infection, Rasmussen’s encephalitis, in which immuno-
label for the MHC-I component, β2m, was present in cortical and
hippocampal neurons (Bien et al., 2002); more recently, MHC-I
immunolabel was observed in dysmorphic/dysphasic cortical
neurons of focal cortical dysplasia, tuberous sclerosis complex and
ganglioglioma cases (Prabowo et al., 2013).
Most of the reports on MHC-I expression in human CNS
neurons have been restricted to early development. In the embryo,
β2m immunolabel was observed at 29–31 gestational weeks in the
LGN of the dorsal thalamus, but was nearly absent by postnatal
day 55, and was completely absent in the adult (Zhang et al.,
2013b). In the human visual cortex, MHC-I was not observed
at any gestational or postnatal stage (Zhang et al., 2013b), while
the expression of MHC-I was very low in the hippocampus at
20 gestational weeks and slowly increased during weeks 27–33. A
rapid increase in MHC-I molecule expression was found in the
subiculum that reached high levels at 31–33 gestational weeks,
but no expression of MHC-I was found in the adult hippocampus
(Zhang et al., 2013a).
Several neurodegenerative disorders including PD are well
established to display neuroinflammatory components and neu-
ronal death (Tansey and Goldberg, 2010). As MHC-I is involved
in antigen presentation and cell death (Chemali et al., 2011),
we investigated its role in the degeneration of catecholamine
neurons that are targeted in PD. Using immunolabel, mass spec-
troscopy, and mRNA analysis from laser captured neurons of
adult control individuals and PD patients (Cebrián et al., 2014),
we found that MHC-I is expressed by SN dopaminergic (DA)
and LC norepinephrinergic (NE) neurons. Further analysis of
isolated neuromelanin (NM) from these neurons by mass spec-
troscopy identified specific HLA alleles of MHC-I recovered from
SN neurons, providing means to genotype the HLA type from
neurons in postmortem human brain. Most of the immuno-
label appeared to be present in NM, which are contained in
modified autophagic lysosomes, but membrane preservation in
postmortem human tissue is too poor to clearly ascertain whether
the MHC-I is actually present on the plasma membrane at the
time of death.
Our data from human tissue were supported by in vitro
experiments that show DA human neurons derived from human
embryonic stem cells normally do not express MHC-I but will do
so following exposure to IFN-γ. Cultured primary catecholamine
murine neurons also normally do not express MHC-I, but do
so upon exposure to IFN-γ, activated microglia or exposure
to high levels of L-dihydroxyphenylalanine (L-DOPA), and are
far more susceptible to MHC-I induction than other neuronal
populations tested, including cortical, striatal and thalamic neu-
rons (Cebrián et al., 2014). These findings suggest that neuronal
MHC-I expression and antigen display in catecholamine neu-
rons may be triggered by microglial activation or high cytoso-
lic DA, which in the presence of the appropriate antigen and
CTLs could play a role in neuronal death during diseases in
which CNS inflammation is robust. Thus, these results suggest
reason to further explore roles for activated microglia, antigen
presentation, neuronal MHC-I expression and recruitment of
CTLs in neurodegenerative diseases, including PD, that feature
the presence of T cells, activated microglia, intracellular oxida-
tive stress and aggregates of alpha-synuclein (α-syn) in the SN
and LC. These data may set a stage for understanding selective
CTLs/MHC-I mediated neurodegeneration and set the basis for
redefining the immunological component of PD, as well as pro-
vide evidence for a novel mechanism of neuronal death due to
T-cell activity on which new therapies and treatments could be
based.
ROLES FOR MHC-I IN BRAIN DEVELOPMENT AND SYNAPTIC
PLASTICITY
It is well established that developing neurons express MHC-I
(Shatz, 2009). A phenomenon implicated in development and
maintenance of neuronal circuitry in the visual system (for review
see Higenell and Ruthazer, 2010), the hippocampus, the cere-
bellum and the cortex (Ribic, 2012). Major histocompatibility
complex I expression by developing neurons may be involved in
retrograde signaling that regulates synaptic structure (Goddard
et al., 2007). Neuronal MHC-I signaling may in some cases require
regulators of cellular differentiation (Potthoff and Olson, 2007)
known as myocyte enhancer factor 2 transcription factors (Elmer
et al., 2013) to eliminate synapses during brain development.
In the visual system, mice deficient for MHC-I or the T
cell receptor (TCR) subunit, CD3zeta (also known as CD247),
exhibit reduced retinal synaptic activity, incomplete develop-
mental refinement of connections between retina and its central
targets, and reduced retinal ganglion cell dendritic motility with
increased dendritic density (Xu et al., 2010). Ocular dominance
plasticity during development was enhanced in mice lacking PirB,
an innate immune receptor that binds MHC-I, or mice lacking
H2-Kb and H2-Db, the two classical MHC-I αchains of C57BL/6
mice (Datwani et al., 2009). Mice that lacked H2-Db and H2-
Kb also showed defects in synapse elimination and formation of
eye-specific layers in visual processing areas of the brain, which
was rescued by restoring H2-Db expression selectively in CNS
neurons (Lee et al., 2014). Interestingly, in retina-thalamic co-
cultures, a soluble form of MHC-I inhibited retinal outgrowth to
thalami that expressed high neuronal MHC-I (Washburn et al.,
2011).
There is also evidence that neuronal MHC-I acts to regu-
late synapses in the hippocampus. An initial report (Corriveau
et al., 1998) showed that MHC-I expression was increased by
seizure. Later reports showed a variety of effects on synaptic
plasticity. In mice deficient for the TCR subunit CD3zeta, hip-
pocampal long-term potentiation was enhanced and long-term
depression was absent (Huh et al., 2000). Other reports indicate
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that neuronal MHC-I inhibits NMDAR function (Fourgeaud
et al., 2010) and is critical for hippocampus-dependent mem-
ory (Nelson et al., 2013). These effects may in part be due
to altered synaptic morphology, as hippocampal neurons with
high levels of MHC-I maintain accelerated neurite outgrowth
and polarization with more primary neurites (Bilousova et al.,
2012). There thus appears to be a number of interacting pathways
that can be influenced by MHC-I expression in hippocampal
synapses.
Neuronal MHC-I expression has also been shown to regulate
long-term depression and limit motor learning in cerebellum
(McConnell et al., 2009) and the density and function of cortical
synapses in vitro and in vivo (Glynn et al., 2011).
ROLES FOR MHC-I IN AXONAL REGENERATION
Neuronal MHC-I expression is further implicated in models
of axonal regeneration. Peripheral nerve transection in MHC-I
knockout mice resulted in more extensive detachments from
presynaptic terminals from perikarya and dendrites of axo-
tomized neurons than wild-type animals (Oliveira et al., 2004).
These results suggest that MHC-I molecules regulate the ability of
neurons to regenerate axons.
A subsequent study found that in mice with strong axonal
regrowth potential, axotomy produced a pronounced upregu-
lation of MHC-I in spinal cord and a rapid loss of afferents,
but that C57BL/6J mice, which exhibit poor axonal regenerative
potential, displayed less MHC-I increase and a slower stripping
of the synapses. These results suggest that neuronal expression
of MHC-I during the first week after lesion enhances axonal
regeneration (Sabha et al., 2008), and support the observation
that elevated neuronal MHC-I expression promotes the recovery
of locomotor abilities after spinal cord injury (Joseph et al., 2011).
It has thus been suggested that MHC-I and MHC-I receptors may
provide new targets to promote neurorepair following injury (Wu
et al., 2011).
Previous data suggest that enhanced levels of neuronal MHC-I
facilitate axonal regeneration, although it is still unclear how this
molecule might help axons to recover after a lesion. Shatz (2009)
have shown that PirB, an immune receptor that binds MHC-I, is
highly expressed in neurons of particular brain regions, including
the cerebral cortex, the olfactory bulb and the cerebellum. PirB
is also located in growth cones and axons of cerebral cortical
neurons in vitro (Syken et al., 2006). It has been proposed
that MHC-I is located postsynaptically near glutamate receptors,
whereas PirB is present presynaptically in axonal growth cones
of cortical neurons in vitro. In that model, PirB would signal
when bound to MHC-I located across the synapse. Since neu-
ral activity regulates MHC-I expression levels, PirB could also
regulate downstream signaling cascades in an activity-dependent
manner (Shatz, 2009). This sequence of events may explain
why an increase of MHC-I/PirB molecules facilitates axonal
regeneration.
An alternate explanation is based on a recent report on
Cx3cr1, a chemokine receptor highly expressed in microglia (Wolf
et al., 2013). Cx3cr1 deficiency causes a transient reduction of
microglia during the early postnatal period and a consequent
deficit in synaptic pruning, which is associated with weak synaptic
transmission and decreased functional brain connectivity (Zhan
et al., 2014). A lack of neuronal MHC-I could be related to a
decrease of microglia, while increased neuronal MHC-I could
promote a higher number of microglial cells that according to
Zhang et al. (2014) could improve synaptic pruning and recovery
of axons after a lesion.
IS NEURONAL MHC-I IMMUNOLOGICALLY FUNCTIONAL?
During a period when neurons were generally regarded as MHC-I
deficient, Medana et al. (2000) identified immunological func-
tions of MHC-I in cultured neurons. They induced MHC-I
and Fas receptor in murine hippocampal neurons with IFN-
γ: the Fas receptor promotes apoptosis when it interacts with
Fas ligand, a type-II transmembrane protein on T cells (Wajant,
2002; Figure 1). The MHC-I positive neurons were then chal-
lenged with the peptide GP33, an epitope of the lymphocytic
choriomeningitis virus envelope glycoprotein, and with allore-
active CTLs to GP33. The MHC-I-expressing neurons pulsed
with GP33, but not a control peptide, were killed by GP33-
specific CTLs in a manner that did not require perforin, a pore-
forming cytolytic protein released from CTLs granules (Tschopp
et al., 1986), but did require Fas/FasL (Medana et al., 2000). A
subsequent study reported that perforin, however, can play a role
in CTL/neuron interactions by silencing neuronal activity prior
to cell death (Meuth et al., 2009). Together, the Medana and
Meuth studies introduced the hypothesis that MHC-I express-
ing neurons could be selectively targeted and destroyed by
T cells.
ROLES FOR NEURONAL MHC-I IN VIRAL MEDIATED
NEUROINFLAMMATION, BRAIN DISEASE AND
NEURODEGENERATION
Pereira and Simmons (1999) showed that the H2 heavy chain
and β2m components of the MHC-I molecule were both present
on the surface of primary sensory neurons within 1–2 weeks
after herpes simplex virus infection; some of these neurons
were in close proximal association with T cells in vivo, sug-
gesting a possible immunological interaction between neuronal
MHC-I and T cells. Such an interaction was recently demon-
strated as brain-isolated CTLs were found to destroy neu-
rons infected with the neurotropic Borna disease virus in an
antigen- and MHC-I dependent manner. Neuronal apopto-
sis were detected only hours after initial contact (Chevalier
et al., 2011). Together, these studies indicate that the virus-
specific CTLs can act as immune effectors in CNS viral
infections.
The identification of neuronal MHC-I expression in human
is relatively recent, starting with a report on a childhood
viral infection, Rasmussen’s encephalitis (Bien et al., 2002).
In human autopsy, immunolabel for the MHC-I component,
β2m, was identified in cortical and hippocampal neurons, and
CTLs were found in close apposition to these neurons. Analysis
of the T cells demonstrated that there were clonal expan-
sions of a subset of CD8+ T cells, but that the distribu-
tion CD4+ cells was normal. Granzyme B, a T cell cytotoxic
molecule, was observed in CTLs in close appositions to neu-
rons and astrocytes (Schwab et al., 2009). Together, these
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data strongly support antigen-driven MHC-I restricted, CTL-
mediated attack against neurons and astrocytes in Rasmussen’s
encephalitis.
Recently, a strong upregulation of neuronal MHC-I was
reported in focal glioneuronal lesions associated with intractable
epilepsy. This induction of MHC-I in neuronal cells may also
be a feature of type II focal cortical dysplasia, tuberous sclerosis
complex and ganglioglioma (Prabowo et al., 2013).
Another recent study suggests that human LilrB2, an immune
cell receptor that binds MHC class I molecules and inhibits
immune response (Barrow and Trowsdale, 2008), is a β-amyloid
receptor, and that its murine homolog PirB regulates synaptic
plasticity in an Alzheimer’s disease rodent model (Kim et al.,
2013).
Multiple sclerosis (MS) has been linked to MHC-I and CTLs
in the CNS (Friese and Fugger, 2005). Axonal injury and loss
is a central determinant of irreversible neurological deficit and
disease progression in patients with MS, and axon injury is most
prominent within active, inflammatory demyelinated MS lesions
enriched in CTLs (Bjartmar and Trapp, 2001). A recent study
shows that axons are injured by antigen-specific CTLs through
a MHC-I and granzyme B-dependent mechanism (Sauer et al.,
2013), and suggests that CTLs may provide therapeutic targets
in MS.
Our findings in human postmortem samples of adult control
individuals and PD patients show that MHC-I is expressed by
SN DA and LC NE neurons (Cebrián et al., 2014) which may
have further implications for neurodegeneration. The proportion
of catecholamine LC neurons that expressed MHC-I in humans
was higher in controls than in PD subjects, which suggests that
neurons with MHC-I expression may be more prone to cell death
during the disease. The preference for MHC-I expression by
catecholamine neurons was replicated in cultured SN DA murine
neurons in which MHC-I was induced by IFN-γ and microglia
activated by NM or α-syn, substances found extracellularly in
postmortem PD brain, or by chronic exposure to the DA pre-
cursor, L-DOPA, which may be related to intracellular oxidative
stress due to high cytosolic levels of its metabolite, DA. We
found that cultured SN murine neurons can process and present
foreign protein antigens by MHC-I, and that in the presence
of the appropriate antigen and CTLs, the neurons are killed by
CTLs (Cebrián et al., 2014). These findings suggest that neuronal
MHC-I expression and antigen display by catecholamine neurons
can be triggered by microglial activation or high cytosolic DA,
features thought to be typical of PD, and that in the presence of
the appropriate antigen and CTLs, MHC-I could play a role in
neuronal death in diseases with robust CNS inflammation.
CONCLUSIONS
Neuronal MHC-I expression plays multiple roles. First, it reg-
ulates synaptic plasticity during brain development. Second, it
regulates axonal regeneration and the appropriate specification
of synaptic inputs following injury. Third, in neuronal dis-
eases including neurotropic viral infections, neuronal MHC-I
expression is upregulated and may initiate T cell mediated
responses. While current research in each of these areas is ongo-
ing, the suggestion of a role in neurodegenerative disease is the
most recent and the least understood: while there is a consensus
that many neurodegenerative diseases feature a robust inflamma-
tory response, it remains unclear how this is related to chronic
disease processes.
Our recent study demonstrates neuronal MHC-I expression
in both normal and PD adult brain; such expression to date
appears to be particular for catecholaminergic/monoaminergic
neurons. In vitro experiments indicate that DA primary
human neurons derived from human embryonic stem cells
and primary catecholamine murine neurons are more susceptible
to MHC-I induction by IFN-γ than other neuronal populations
(Cebrián et al., 2014), which may be related to unusually high
oxidative stress in these neurons. The findings suggest that an
immunologically-based mechanism may link activated microglia,
increased cytosolic oxidative stress and neuronal death of
catecholamine neurons in PD and other diseases of this system.
For PD, microglia activated by NM, native α-syn, modified α-syn,
or mutant α-syn release IFN-γ that in turn can induce MHC-I
expression in these neurons. The capacity of catecholamine
neurons to process and display antigens may thus render them
selective targets for T cell mediated cell death.
These possibilities are consistent with recent demonstrations
that microglia can be activated by substances released from
degenerating neurons in PD, such as α-syn (Zhang et al., 2007;
Béraud et al., 2013) or NM (Zhang et al., 2011, 2013c), and that
activated microglia can elicit neurotoxicity (Block et al., 2007;
Lull and Block, 2010; Zhao et al., 2013). Both NM and α-syn are
found extracellularly in the postmortem brain of PD patients
(Double, 2012), a disorder that features high levels of activated
microglia in the SN (Foix and Nicolesco, 1925) and high levels of
intracellular oxidative stress (Fahn and Sulzer, 2004). Parkinson’s
disease patient brain features increased IFN-γ (Mogi et al., 2007)
and chemokines (Harris et al., 2012), as well as a compromised
blood brain barrier (Farkas et al., 2000; German et al., 2012) that
may explain why CTLs are substantially higher in PD patients
than age-matched controls (Hisanaga et al., 2001; Brochard et al.,
2009). CD4+ T helper cells have also been shown to infiltrate the
brain in human PD postmortem samples and exert a cytotoxic
effect in mouse brain following nigrostriatal injury (Brochard
et al., 2009); thus, T cells and antigen presentation, as well as
activated microglia could play a role in PD pathogenesis.
Neuronal display of antigenic MHC-I could participate in a
range of additional neurological disorders. For example, Japanese
encephalitis virus can induce MHC-I expression in non-neuronal
cells by interferon type 1 (Abraham et al., 2010), while in
mice, IFN-γ plays a role in paraquat-induced neurodegeneration
(Mangano et al., 2012). Central nervous system-directed expres-
sion of IFN-γ produces basal ganglia calcification and nigros-
triatal degeneration (Chakrabarty et al., 2011). In human case
studies, a link is described between chronic hepatitis C patients
who were treated with type 1 interferon and developed PD-like
symptoms that reversed when the treatment was halted (Almeida
et al., 2009).
Together, these data indicate that in human brain, neuronal
MHC-I expression, antigen presentation and the presence of
T cells could occur simultaneously under certain circum-
stances, leading to the death of targeted neurons. In some
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FIGURE 2 | Scheme modeling an initial insult and disruption of the
blood brain barrier, with penetration of lymphocytes into the brain.
In the event of death of a few catecholamine neurons, alpha-synuclein
(α-syn) and neuromelanin (NM) are released to the extracellular space,
activating microglial cells that in turn release proinflammatory
substances such as interferon gamma (IFN-γ). This would induce major
histocompatibility class I expression (MHC-I) in the membrane of
catecholamine neurons, and if they contain proteins that are misfolded
or cannot be normally degraded, these might be presented as antigens
by MHC-I. Cytotoxic lymphocytes that enter the brain may recognize
these presented antigens and kill the neurons, which would again
release α-syn and NM. This could continue a vicious cycle that may
contribute to the death of catecholamine neurons in Parkinson’s
disease.
neurodegenerative diseases, and in particular for PD, we propose
that activation of lymphocytes in the periphery may occur in
response to self or non-self proteins, or as an initial insult and
disruption of the blood brain barrier, with a subsequent penetra-
tion of lymphocytes in the brain. When catecholamine neurons
die with subsequent release of α-syn and NM to the extracellular
space, the activation of microglial cells will release proinflam-
matory substances such as IFN-γ, leading to an upregulation of
MHC-I in the membrane of catecholamine neurons that could
present neuronally derived antigens. If lymphocytes are close,
they could recognize these antigens and target and kill the cell,
which would again release α-syn and NM (Figure 2), leading to
a vicious cycle that would enhance with time the neuronal death
and pathogenesis of PD.
Future studies are necessary to identify which antigens are
presented by MHC-I expressing catecholamine neurons and how
T cells might interact with them. If these interactions occur,
immune therapies used in other diseases including classical
autoimmune disorders such as Type 1 diabetes or MS may be
adapted to provide future treatments for PD.
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